Orchard Therapeutics plc
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Orchard Therapeutics plc, a commercial-stage biotechnology company, develops and commercializes ex vivo autologous hematopoietic stem cell (HSC) gene therapies for severe genetic and rare diseases, including neurometabolic disorders, primary immune deficiencies and blood disorders; its approved products include Libmeldy (atidarsagene autotemcel, known as Lenmeldy in the US) for metachromatic leukodystrophy (MLD) and Strimvelis for adenosine deaminase severe combined immunodeficiency (ADA-SCID); the company advances a pipeline of investigational HSC gene therapies such as OTL-203 for mucopolysaccharidosis type I (MPS-I), OTL-201 for MPS-IIIA, OTL-300 for beta-thalassemia, OTL-204 for frontotemporal dementia and preclinical programs including OTL-104 for Crohn's disease and OTL-105 for hereditary angioedema. Founded in 2015 and headquartered at 245 Hammersmith Road, London, United Kingdom, Orchard Therapeutics operates primarily in North America and Europe, with offices in Boston and collaborations with institutions such as University College London, Great Ormond Street Hospital, the University of Manchester and San Raffaele-Telethon Institute for Gene Therapy. As a subsidiary of Kyowa Kirin Co., Ltd. following its acquisition in January 2024, the company recently achieved FDA approval for Lenmeldy in 2024 for pre-symptomatic and early-symptomatic MLD in children, secured reimbursed access agreements for Libmeldy with the Beneluxa Initiative in 2024 and the Spanish National Health System in 2025, and continues to expand commercialization efforts in Europe, the UK, Switzerland, Iceland, Liechtenstein and Norway while advancing registrational studies and early pipeline programs.
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
Orchard Therapeutics Celebrates Addition of Metachromatic Leukodystrophy to the U.S. Recommended Uniform Screening Panel
Orchard Therapeutics Announces Last Patient Treated in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Orchard Therapeutics Announces Reimbursement Agreement in Spain
Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
Orchard Therapeutics Announces Multiple Data Presentations and Publications
Orchard Therapeutics and Er-Kim Announce Partnership to Broaden Access to Libmeldy to Eligible Patients in Turkey and Certain Eurasian Countries
Orchard Therapeutics Announces Multiple Presentations from across its Late-stage Neurometabolic Portfolio at SSIEM 2024
Orchard Therapeutics Celebrates Global Progress toward Advancing Newborn Screening for MLD on International Neonatal Screening Day
Sorrento Therapeutics (OTCMKTS:SRNEQ) and bluebird bio (NASDAQ:BLUE) Financial Comparison
Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024
Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List
Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy
Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.
US approves first gene therapy for rare genetic disease
Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
Kyowa Kirin Successfully Completes Acquisition of Orchard Therapeutics, a Global Gene Therapy Leader for Rare Diseases